-$0.31 Earnings Per Share Expected for ADMA Biologics Inc (ADMA) This Quarter

Share on StockTwits

Wall Street analysts expect that ADMA Biologics Inc (NASDAQ:ADMA) will announce ($0.31) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for ADMA Biologics’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.32). ADMA Biologics reported earnings per share of $0.59 during the same quarter last year, which would indicate a negative year over year growth rate of 152.5%. The company is scheduled to issue its next quarterly earnings report on Friday, November 2nd.

On average, analysts expect that ADMA Biologics will report full-year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.26). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.93) to $0.00. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.66 million for the quarter, compared to analyst estimates of $5.35 million.

A number of brokerages recently weighed in on ADMA. ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. LADENBURG THALM/SH SH dropped their price objective on ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday, June 13th. Oppenheimer began coverage on ADMA Biologics in a report on Thursday, July 12th. They set a “buy” rating and a $13.00 price objective on the stock. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of ADMA Biologics in a report on Wednesday, September 5th. Seven equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $9.50.

A number of institutional investors and hedge funds have recently bought and sold shares of ADMA. Millennium Management LLC boosted its position in ADMA Biologics by 254.0% during the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 48,455 shares in the last quarter. BlackRock Inc. boosted its position in ADMA Biologics by 59.5% during the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 15,115 shares in the last quarter. Spark Investment Management LLC purchased a new stake in ADMA Biologics during the first quarter worth $102,000. JPMorgan Chase & Co. purchased a new stake in shares of ADMA Biologics in the first quarter valued at $182,000. Finally, Element Capital Management LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at $118,000. Institutional investors own 55.08% of the company’s stock.

ADMA stock traded up $0.01 on Friday, reaching $6.58. 40 shares of the company’s stock were exchanged, compared to its average volume of 171,372. ADMA Biologics has a twelve month low of $2.01 and a twelve month high of $6.96. The firm has a market capitalization of $300.80 million, a PE ratio of -3.45 and a beta of 2.35. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply